Sanofi SNY reported second-quarter 2025 adjusted earnings of 90 cents per American depositary share, which missed the Zacks ...

In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a ...

The clinical trial was sponsored by Sanofi, the developer of tolebrutinib. More information The Cleveland Clinic has more on tyrosine kinase inhibitors.